US 12,329,745 B2
Methods and compositions for treating glucocorticoid excess
David A. Katz, Portland, OR (US)
Assigned to Sparrow Pharmaceuticals, Inc., Portland, OR (US)
Filed by Sparrow Pharmaceuticals, Inc., Portland, OR (US)
Filed on Apr. 8, 2024, as Appl. No. 18/629,056.
Application 18/629,056 is a division of application No. 18/321,266, filed on May 22, 2023, abandoned.
Application 18/321,266 is a continuation of application No. PCT/US2023/067057, filed on May 16, 2023.
Claims priority of provisional application 63/364,759, filed on May 16, 2022.
Prior Publication US 2024/0293375 A1, Sep. 5, 2024
Int. Cl. A61P 5/46 (2006.01); A61K 9/00 (2006.01); A61K 31/4196 (2006.01); A61K 45/06 (2006.01); A61P 3/10 (2006.01); A61P 5/44 (2006.01)
CPC A61K 31/4196 (2013.01) [A61K 9/0053 (2013.01); A61K 45/06 (2013.01); A61P 5/44 (2018.01)] 15 Claims
 
1. A method for treating diabetes and lowering intracellular cortisol level in a human patient with diabetes and an elevated level of cortisol, comprising administering to the patient a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, wherein the compound is:

OG Complex Work Unit Chemistry
and
wherein the therapeutically effective amount of the compound, or the pharmaceutically acceptable salt thereof, is about 1 mg to about 40 mg daily; wherein the treatment decreases the patient's hemoglobin A1c (HbA1c) levels compared to the patient's HbA1c levels before the compound is initially administered to the patient; and wherein the compound does not show tachyphylaxis for HSD-1 inhibition in human adipose tissue.